Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 8NIH 8NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 166Lymphoid 21Other hematologic neoplasm 10Thoracic 5Tumor-Agnostic 3Other solid neoplasm 2Genitourinary 2Gastrointestinal 2Sarcoma 1Myeloid 1Gynecologic 1CNS 1

Conditions

Advanced Solid Tumors 1Advanced Non-Small Cell Lung Cancer 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Bortezomib × Other solid neoplasm × Clear all
NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Astellas Pharma Inc

Phase 2 Completed
13 enrolled
Other solid neoplasm

Advanced Solid Tumors

NCT00064636 2005-06-24

Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

Millennium Pharmaceuticals, Inc.

Phase 1 Terminated
46 enrolled
Other solid neoplasmThoracic

Advanced Non-Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡